The Randomized Aldactone Evaluation Study (RALES) and the Eplerenone Postacute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) suggested that an MR antagonist on top of an ACEI or an ARB can reduce mortality in patients with severe congestive heart failure and left ventricular dysfunction after MI [15, 18]. The gene discussed is NR3C2; the disease is congestive heart failure.